Table 2. Studies that compare single-dose SRS and hFSRT in brain metastases.
| Studies | n | Dose/fr | WBRT | LC | Overall Survival | Toxicity |
|---|---|---|---|---|---|---|
| Kim et al. 2011 [1] | Single-dose SRS: 58 patients (81 lesions) hFSRT: 40 patients (49 lesions) |
20 Gy/1 fr 36 Gy/6 fr | Single-dose SRS: 12 patients hFSRT 16 patients | 16% CR 7% PD 15% CR 0% PD |
MS 16 | 17% single-dose SRS 5% hFSRT P=0.05 |
| Minniti et al. 2016 [8] | 289 patients 343 lesions y>2cm |
18 Gy/1 fr o 15-16 Gy si >3 cm 27 Gy/3 fr |
5 patients | Single-dose SRS: 77% hFSRT: 91% |
1-y 58% 2-y 24% |
20% single-dose SRS RN 8% hFSRT RN |
| Feuvret [15] | 24 patients single-dose SRS 12 patients hFSRT |
14 Gy/1 fr >3 cm 23.1 Gy/3 fr |
- | 58% 100% |
MS 5.5 m MS 16.8 m | 6 patients G1-2 2 patients G2 |
| Donovan et al. 2019 [27] | 90 patients | 24 Gy/1 fr 21 Gy/3 fr |
12 patients | Recurrence 8 patients 6 patients single-dose SRS 2 patients hFSRT |
MS 11.7 m | 16p RN (21/62 lesions; 4 symptomatic RN) 10 patients 1 fr 11 patients 3fr |
| Present study | 97 patients (135 lesions) 56 patients Single-dose SRS 41 patients hFSRT |
I: 12-15 Gy/1 fr II: 16-20 Gy/1 fr III: 30 Gy/5-6 fr |
16 patients 10 patients 12 patients |
82.6% 78.2% 93.7% |
MS 10 m | Single-dose: Acute grade 1-2: 29% Late: 7.1% hFSRT: Acute grade 1-2: 23% Late: 19.5% |
SRS: Stereotactic radiosurgery, hFSRT: Hypofractionated stereotactic radiotherapy, WBRT: Whole-brain radiotherapy, CR: Complete response, PD: Progression disease, MS: Median survival, RN: Radionecrosis